
- /
- Supported exchanges
- / TO
- / EDT.TO
Spectral Med Inc (EDT TO) stock market data APIs
Spectral Med Inc Financial Data Overview
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Spectral Med Inc data using free add-ons & libraries
Get Spectral Med Inc Fundamental Data
Spectral Med Inc Fundamental data includes:
- Net Revenue: 2 190 K
- EBITDA: -13 429 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-09
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Spectral Med Inc News

Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic...


Spectral Medical Announces First Quarter and Provides Corporate Update
Tigris Trial Enrollment completedTopline results expected to be released in August 2025Entered into an up to US$10 million Promissory Note with Vantive to Fund Spectral to PMX commercialization TORON...

Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive
• Non-Dilutive Financing • Up to US$10 Million Promissory Note Provided by Vantive • If Fully Drawn, Promissory Note is Expected to Fully Fund Spectral to PMX Commercialization • Co...

Spectral Medical Announces Fourth Quarter and Fiscal 2024 Results and Provides Corporate Update
TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and sept...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.